UK pharmaceutical company Pharmanovia announced on Monday the expansion of its neurology portfolio through the acquisition of 11 central nervous system (CNS) brands from French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY).

These acquired brands address unmet needs across four distinct therapy areas related to CNS disorders, covering psycholeptic, anxiolytic, anti-epileptic and anti-psychotic medications. Included among them are Frisium (clobazam), Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren, Castilium and Gardenal (phenobarbital). Clobazam, classified as a benzodiazepine, is effective in treating anxiety, psychiatric conditions and epilepsy, while phenobarbital serves as an anti-convulsant for various forms of epilepsy.

This portfolio spans over 60 markets, significantly strengthening Pharmanovia's presence in key regions such as Brazil, South Africa, France and Italy.

The acquisition complements Pharmanovia's existing neurology portfolio and commercial capabilities, and underscores its commitment to expanding its presence in the CNS therapeutic landscape.